Synergistic effects of LY294002 and ABT199 on the cell cycle in K562, HL60 and KG1a cells
- Authors:
- Yinghua Geng
- Wenjuan Wu
- Lili Zhou
- Jun Li
- Yingbao Geng
- Yanli Yang
-
Affiliations: Department of Hematology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui 233004, P.R. China, Department of Biochemistry and Molecular Biology, Bengbu Medical College, Bengbu, Anhui 233000, P.R. China, College of Medical Information Engineering, Anhui University of Chinese Medicine, Hefei, Anhui 230012, P.R. China - Published online on: April 12, 2021 https://doi.org/10.3892/or.2021.8048
- Article Number: 97
This article is mentioned in:
Abstract
 |
 |
 |
 |
 |
 |
|
Sakamoto KM, Grant S, Saleiro D, Crispino JD, Hijiya N, Giles F, Platanias L and Eklund EA: Targeting novel signaling pathways for resistant acute myeloid leukemia. Mol Genet Metab. 114:397–402. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Horner MJ, Ries LAG, Krapcho M, Neyman N, Aminou R, Howlader N, Altekruse SF, Feuer EJ, Huang L, Mariotto A, Miller BA, et al: SEER Cancer Statistics Review, 1975–2006. National Cancer Institute; Bethesda, MD: 2009 | |
|
Pan R, Hogdal LJ, Benito JM, Bucci D, Han L, Borthakur G, Cortes J, DeAngelo DJ, Debose L, Mu H, et al: Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. Cancer Discov. 4:362–375. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Stuani L, Sabatier M and Sarry JE: Exploiting metabolic vulnerabilities for personalized therapy in acute myeloid leukemia. BMC Biol. 17:572019. View Article : Google Scholar : PubMed/NCBI | |
|
Staudt D, Murray HC and McLachlan T: Targeting oncogenic signaling in mutant FLT3 acute myeloid leukemia: The path to least resistance. Int J Mol Sci. 19:31982018. View Article : Google Scholar : PubMed/NCBI | |
|
Kantarjian HM: Therapy for elderly patients with acute myeloid leukemia: A problem in search of solutions. Cancer. 109:1007–1010. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Kantarjian H, O'Brien S, Cortes J, Giles F, Faderl S, Jabbour E, Garcia-Manero G, Wierda W, Pierce S, Shan J and Estey E: Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: Predictive prognostic models for outcome. Cancer. 106:1090–1098. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Nazha A and Ravandi F: Acute myeloid leukemia in the elderly: Do we know who should be treated and how? Leuk Lymphoma. 55:979–987. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Döhner H, Estey EH, Amadori S, Appelbaum FR, Büchner T, Burnett AK, Dombret H, Fenaux P, Grimwade D, Larson RA, et al: Diagnosis and management of acute myeloid leukemia in adults: Recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 115:453–474. 2010. View Article : Google Scholar | |
|
Lerch E, Espeli V, Zucca E, Leoncini L, Scali G, Mora O, Bordoni A, Cavalli F and Ghielmini M: Prognosis of acute myeloid leukemia in the general population: Data from southern Switzerland. Tumori. 95:303–310. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Yu S, Xiong Y, Xu J, Liang X, Fu Y, Liu D, Yu X and Wu D: Identification of dysfunctional gut microbiota through rectal swab in patients with different severity of acute pancreatitis. Dig Dis Sci. 65:3223–3237. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Engelman JA: Targeting PI3K signalling in cancer: Opportunities, challenges and limitations. Nat Rev Cancer. 9:550–562. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Park S, Chapuis N, Tamburini J, Bardet V, Cornillet-Lefebvre P, Willems L, Green A, Mayeux P, Lacombe C and Bouscary D: Role of the PI3K/AKT and mTOR signaling pathways in acute myeloid leukemia. Haematologica. 95:819–828. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Vanhaesebroeck B, Stephens L and Hawkins P: PI3K signalling: The path to discovery and understanding. Nat Rev Mol Cell Biol. 13:195–203. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Fransecky L, Mochmann LH and Baldus CD: Outlook on PI3K/AKT/mTOR inhibition in acute leukemia. Mol Cell Ther. 3:22015. View Article : Google Scholar : PubMed/NCBI | |
|
Lindblad O, Cordero E, Puissant A, Macaulay L, Ramos A, Kabir NN, Sun J, Vallon-Christersson J, Haraldsson K, Hemann MT, et al: Aberrant activation of the PI3K/mTOR pathway promotes resistance to sorafenib in AML. Oncogene. 35:5119–5131. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Kulsoom B, Shamsi TS, Afsar NA, Memon Z, Ahmed N and Hasnain SN: Bax, Bcl-2, and Bax/Bcl-2 as prognostic markers in acute myeloid leukemia: Are we ready for Bcl-2-directed therapy? Cancer Manag Res. 10:403–416. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Bhola PD and Letai A: Mitochondria-judges and executioners of cell death sentences. Mol Cell. 61:695–704. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
DeStefano CB and Hourigan CS: Personalizing initial therapy in acute myeloid leukemia: Incorporating novel agents into clinical practice. Ther Adv Hematol. 9:109–121. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Lagadinou ED, Sach A, Callahan K, Rossi RM, Neering SJ, Minhajuddin M, Ashton JM, Pei S, Grose V, O'Dwyer KM, et al: BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells. Cell Stem Cell. 12:329–341. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Campos L, Rouault JP, Sabido O, Oriol P, Roubi N, Vasselon C, Archimbaud E, Magaud JP and Guyotat D: High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Blood. 81:3091–3096. 1993. View Article : Google Scholar : PubMed/NCBI | |
|
Konopleva M, Konoplev S, Hu W, Zaritskey AY, Afanasiev BV and Andreeff M: Stromal cells prevent apoptosis of AML cells by up-regulation of anti-apoptotic proteins. Leukemia. 16:1713–1724. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Matsunaga T, Takemoto N, Sato T, Takimoto R, Tanaka I, Fujimi A, Akiyama T, Kuroda H, Kawano Y, Kobune M, et al: Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia. Nat Med. 9:1158–1165. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Hazlehurst LA, Argilagos RF and Dalton WS: Beta1 integrin mediated adhesion increases Bim protein degradation and contributes to drug resistance in leukaemia cells. Br J Haematol. 136:269–275. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Tabe Y, Jin L, Tsutsumi-Ishii Y, Xu Y, McQueen T, Priebe W, Mills GB, Ohsaka A, Nagaoka I, Andreeff M and Konopleva M: Activation of integrin-linked kinase is a critical prosurvival pathway induced in leukemic cells by bone marrow-derived stromal cells. Cancer Res. 67:684–694. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Kojima K, McQueen T, Chen Y, Jacamo R, Konopleva M, Shinojima N, Shpall E, Huang X and Andreeff M: p53 activation of mesenchymal stromal cells partially abrogates microenvironment-mediated resistance to FLT3 inhibition in AML through HIF-1α-mediated down-regulation of CXCL12. Blood. 118:4431–4439. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Roche S, Koegl M and Courtneidge SA: The phosphatidylinositol 3-kinase alpha is required for DNA synthesis induced by some, but not all, growth factors. Proc Natl Acad Sci USA. 91:9185–9189. 1994. View Article : Google Scholar : PubMed/NCBI | |
|
Shivakrupa R, Bernstein A, Watring N and Linnekin D: Phosphatidylinositol 3′-kinase is required for growth of mast cells expressing the kit catalytic domain mutant. Cancer Res. 63:4412–4419. 2003.PubMed/NCBI | |
|
West KA, Castillo SS and Dennis PA: Activation of the PI3K/Akt pathway and chemotherapeutic resistance. Drug Resist Updat. 5:234–248. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Martelli AM, Tabellini G, Bortul R, Tazzari PL, Cappellini A, Billi AM and Cocco L: Involvement of the phosphoinositide 3-kinase/Akt signaling pathway in the resistance to therapeutic treatments of human leukemias. Histol Histopathol. 20:239–252. 2005.PubMed/NCBI | |
|
Luo J, Manning BD and Cantley LC: Targeting the PI3K-Akt pathway in human cancer: Rationale and promise. Cancer Cell. 4:257–262. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Zhou F, Mei H, Wu Q and Jin R: Expression of histone H2AX phosphorylation and its potential to modulate adriamycin resistance in K562/A02 cell line. J Huazhong Univ Sci Technolog Med Sci. 31:154–158. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Daver N, Cortes J, Kantarjian H and Ravandi F: Acute myeloid leukemia: Advancing clinical trials and promising therapeutics. Expert Rev Hematol. 9:433–445. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Pollyea DA, Stevens BM, Jones CL, Winters A, Pei S, Minhajuddin M, D'Alessandro A, Culp-Hill R, Riemondy KA, Gillen AE, et al: Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia. Net Med. 24:1859–1866. 2018. View Article : Google Scholar | |
|
Li H, Li J, Cheng J, Chen X, Zhou L and Li Z: AML-derived mesenchymal stem cells upregulate CTGF expression through the BMP pathway and induce K562-ADM fusiform transformation and chemoresistance. Oncol Rep. 42:1035–1046. 2019.PubMed/NCBI | |
|
Manda-Handzlik A, Bystrzycka W, Wachowska M, Sieczkowska S, Stelmaszczyk-Emmel A, Demkow U and Ciepiela O: The influence of agents differentiating HL-60 cells toward granulocyte-like cells on their ability to release neutrophil extracellular traps. Immunol Cell Biol. 96:413–425. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
She M, Niu X, Chen X, Li J, Zhou M, He Y, Le Y and Guo K: Resistance of leukemic stem-like cells in AML cell line KG1a to natural killer cell-mediated cytotoxicity. Cancer Lett. 318:173–179. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Wang Y, Kuramitsu Y, Baron B, Kitagawa T, Tokuda K, Akada J, Maehara SI, Maehara Y and Nakamura K: PI3K inhibitor LY294002, as opposed to wortmannin, enhances AKT phosphorylation in gemcitabine-resistant pancreatic cancer cells. Int J Oncol. 50:606–612. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Chiou JT, Lee YC, Huang CH, Shi YJ, Wang LJ and Chang LS: Autophagic HuR mRNA degradation induces survivin and MCL1 downregulation in YM155-treated human leukemia cells. Toxicol Appl Pharmacol. 387:1148572020. View Article : Google Scholar : PubMed/NCBI | |
|
Zhu H, Huang M, Ren D, He J, Zhao F, Yi C and Huang Y: The synergistic effects of low dose fluorouracil and TRAIL on TRAIL-resistant human gastric adenocarcinoma AGS cells. Biomed Res Int. 2013:2938742013. View Article : Google Scholar : PubMed/NCBI | |
|
Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Xu Q, Simpson SE, Scialla TJ, Bagg A and Carroll M: Survival of acute myeloid leukemia cells requires PI3 kinase activation. Blood. 102:972–980. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Kojima K, Shimanuki M, Shikami M, Samudio IJ, Ruvolo V, Corn P, Hanaoka N, Konopleva M, Andreeff M and Nakakuma H: The dual PI3 kinase/mTOR inhibitor PI-103 prevents p53 induction by Mdm2 inhibition but enhances p53-mediated mitochondrial apoptosis in p53 wild-type AML. Leukemia. 22:1728–1736. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Park S, Chapuis N, Bardet V, Tamburini J, Gallay N, Willems L, Knight ZA, Shokat KM, Azar N, Viguié F, et al: PI-103, a dual inhibitor of Class IA phosphatidylinositide 3-kinase and mTOR, has antileukemic activity in AML. Leukemia. 22:1698–1706. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Chen W, Drakos E, Grammatikakis I, Schlette EJ, Li J, Leventaki V, Staikou-Drakopoulou E, Patsouris E, Panayiotidis P, Medeiros LJ and Rassidakis GZ: mTOR signaling is activated by FLT3 kinase and promotes survival of FLT3-mutated acute myeloid leukemia cells. Mol Cancer. 9:2922010. View Article : Google Scholar : PubMed/NCBI | |
|
Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen J, Dayton BD, Ding H, Enschede SH, Fairbrother WJ, et al: ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 19:202–208. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Phase I study of ABT-199 (GDC-0199) in patients with relapsed/refractory non-Hodgkin lymphoma, . Responses observed in diffuse large B-cell (DLBCL) and follicular lymphoma (FL) at higher cohort doses. Clin Adv Hematol Oncol. 12((8 Suppl 16)): S18–S19. 2014. | |
|
Roberts AW, Davids MS, Pagel JM, Kahl BS, Puvvada SD, Gerecitano JF, Kipps TJ, Anderson MA, Brown JR, Gressick L, et al: Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med. 374:311–322. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Nii T, Prabhu VV, Ruvolo V, Madhukar N, Zhao R, Mu H, Heese L, Nishida Y, Kojima K, Garnett MJ, et al: Imipridone ONC212 activates orphan G protein-coupled receptor GPR132 and integrated stress response in acute myeloid leukemia. Leukemia. 33:2805–2816. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Chen JY, Wang MC and Hung WC: Bcr-Abl-induced tyrosine phosphorylation of Emi1 to stabilize Skp2 protein via inhibition of ubiquitination in chronic myeloid leukemia cells. J Cell Physiol. 226:407–413. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Sabri S, Keyhani M and Akbari MT: Whole exome sequencing of chronic myeloid leukemia patients. Iran J Public Health. 45:346–352. 2016.PubMed/NCBI | |
|
Yue ZX, Gao RQ, Gao C, Liu SG, Zhao XX, Xing TY, Niu J, Li ZG, Zheng HY and Ding W: The prognostic potential of coilin in association with p27 expression in pediatric acute lymphoblastic leukemia for disease relapse. Cancer Cell Int. 18:1062018. View Article : Google Scholar : PubMed/NCBI | |
|
Haferlach C, Bacher U, Kohlmann A, Schindela S, Alpermann T, Kern W, Schnittger S and Haferlach T: CDKN1B, encoding the cyclin-dependent kinase inhibitor 1B (p27), is located in the minimally deleted region of 12p abnormalities in myeloid malignancies and its low expression is a favorable prognostic marker in acute myeloid leukemia. Haematologica. 96:829–836. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Fasihi-Ramandi M, Moridnia A, Najafi A and Sharifi M: Inducing apoptosis and decreasing cell proliferation in human acute promyelocytic leukemia through regulation expression of CASP3 by Let-7a-5p blockage. Indian J Hematol Blood Transfus. 34:70–77. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Marsden VS, O'Connor L, O'Reilly LA, Silke J, Metcalf D, Ekert PG, Huang DCS, Cecconi F, Kuida K, Tomaselli KJ, et al: Apoptosis initiated by Bcl-2-regulated caspase activation independently of the cytochrome c/Apaf-1/caspase-9 apoptosome. Nature. 419:634–637. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Endo A, Tomizawa D, Aoki Y, Morio T, Mizutani S and Takagi M: EWSR1/ELF5 induces acute myeloid leukemia by inhibiting p53/p21 pathway. Cancer Sci. 107:1745–1754. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Cahan P and Graubert TA: Integrated genomics of susceptibility to alkylator-induced leukemia in mice. BMC Genomics. 11:6382010. View Article : Google Scholar : PubMed/NCBI |
